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Abstract
Macrophage migration Inhibitory Factor (MIF) is a pro-inflammatory cytokine
sustaining the acute response to gram–negative bacteria and a regulatory role for
MIF in Cystic Fibrosis has been suggested by the presence of a functional,
polymorphic, four-nucleotide repeat in this gene’s promoter at position 2794, with
the 5-repeat allele displaying lower promoter activity. We aimed at assessing the
association of this polymorphism with disease severity in a group of Cystic Fibrosis
patients homozygous for F508del CFTR gene mutation. Genotype frequencies
were determined in 189 Cystic Fibrosis and 134 control subjects; key clinical
features of patients were recorded and compared among homozygous 5-allele
patients and the other MIF genotypes. Patients homozygous for the 5-repeat allele
of MIF promoter displayed a slower rate of lung function decline (p50.027) at
multivariate survival analysis. Multiple regression analysis on age-normalized
respiratory volume showed no association of the homozygous 5-repeat genotype
with lung function under stable conditions and no correlation with P.aeruginosa
chronic colonization. Therefore, only the Homozygous 5-repeat genotype at MIF
2794 is associated with milder disease in F508del Cystic Fibrosis patients.
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Introduction
Cystic fibrosis (CF) is the most common, severe, inherited disorder in the
Caucasian population. It is caused by mutations in the CF Transmembrane
conductance Regulator (CFTR) gene and mainly characterized by bronchopul-
monary disease, pancreatic insufficiency and male infertility. Patients with
identical CFTR genotypes can display markedly different phenotypic expression
[1, 2] and modifier genes were previously described among the factors causing this
discrepancy [3, 4]. Macrophage Migration Inhibitory Factor (MIF) is a key pro-
inflammatory mediator [5]: it sustains an acute inflammatory response both
directly, by inducing cytokines secretion, and indirectly, by overriding the anti-
inflammatory activity of glucocorticoids [6]. MIF plays a significant role in
immune and inflammatory-based diseases such as asthma [7], rheumatoid
arthritis [8], acute respiratory distress syndrome [9] and septic shock [10, 11].
Although MIF is involved in the defence against severe infection, modulation of
the high cytokine levels elicited by its action may prevent harmful effects during
the inflammatory response. Indeed, lethal sepsis induced in mice by lipopoly-
saccharide (LPS) or E. coli causes increased mortality in the presence of
recombinant MIF [12], while anti–MIF neutralizing antibodies were able to
protect mice from lethal endotoxic sepsis induced by bacterial (E. coli) peritonitis
[11]. It has also been suggested that neutralizing MIF could lead to improved
resistance against P. aeruginosa infection, since clearance of the bacteria following
tracheal instillation was improved in MIF-knockout mice [10]. Recently, Baugh et
al. [13] identified a functionally significant polymorphism in the human MIF
gene, consisting of a four-nucleotide CATT repeat located at position 2794 of the
MIF promoter (MIF-CATT). In an in vitro model, the 5-CATT repeat showed
significantly lower transcriptional activity when compared to the 6-, 7- or 8-CATT
repeat alleles. This polymorphism is reported as a TTCA insertion or deletion
relative to the 6-repeats genotype in NCBI dbSNP entries rs3063368 and
rs36224313 respectively, at the genomic coordinates (UCSC genome browser
– hg19) chr22:24235773-24235772. Five percent of healthy subjects are
homozygous for the 5-CATT repeat allele. Homozygosity for this allele was
significantly associated with milder forms of rheumatoid arthritis, suggesting it
may have a protective effect. In CF patients, Plant et al. [14] reported a significant
decrease in both P. aeruginosa colonization and pancreatic insufficiency among
adult patients carrying at least one 5-CATT MIF allele. Since many studies of
modifier genes in CF have yielded conflicting results, it is essential to validate any
association in a new, independent population and MIF gene is no exception [4].
This study aimed at clarifying and validating the association between MIF-CATT
repeats and disease severity in a more homogeneous cohort of CF patients with
homozygous F508del CFTR mutation. Given the biological relationship between
MIF and acute inflammation suggested by the above cited literature, we chose as a
primary outcome the time to the first acute episode causing forced expiratory
volume (FEV1) to fall below the 60% of the predicted value. We also verified the
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possible relationship between MIF and age-normalized FEV1 and chronic P.
aeruginosa colonization under stable conditions.
Materials and Methods
Study population
One hundred and eighty-nine CF patients homozygous for the F508del mutation
were recruited from two European centres (Verona: 138, Brussels: 51). All of the
patients were able to perform reliable spirometry. A cohort of 134 adult Italian
subjects was used as control. Healthy subjects were negative for the most common
mutations of the CFTR gene, except for 4 heterozygous subjects (healthy carriers).
This is consistent with epidemiological data about carrier frequency in Europe.
This study was approved by the Ethics Committee of the University and Hospital
Trust of Verona (protocol #24737); informed signed consent for DNA analysis
was obtained from participants or from their parents, as required.
Genotyping
DNA was extracted from whole blood using the salting out method, then samples
were genotyped for the polymorphism of MIF promoter (varying number of
CATT repeats) at -794. DNA was amplified by Polymerase Chain Reaction (PCR)
in a GeneAmp PCRsystem 9700H (Applied Biosystem, Foster City, CA, USA) as
previously described [13]. Genotyping was performed by the BMR Genomics
Sequencing Service (CRIBI, University of Padova, Italy). Results were analysed
using GenescanView 1.2 software (CRIBI, University of Padova, Italy).
Clinical data of CF patients
Clinical data for the 189 patients were collected in electronic databases. Main
characteristics and MIF genotype of the patients are summarized in table 1 and
extensively reported in S1 Table. Anthropometric parameters and forced
expiratory volume (FEV1) were normalized using Freeman’s [15] and Knudson’s
[16] equations respectively. Given the accelerated FEV1 decline with age in CF
patients, the last value of FEV1 was expressed as FEV1 percentile using CF-specific
reference equations [17]. Diabetes was defined by the need for insulin therapy.
Chronic P. aeruginosa colonization was reported using a European consensus
definition [18]. In brief, chronic colonization was defined as the isolation of at
least 3 isolates in a six month period (at minimum 30 days interval) while
sporadic colonization referred to the isolation of P. aeruginosa in the bronchial
tree in presence or absence of inflammation.
Statistical analysis and study design
Given the involvement of MIF in acute inflammation, we focused on the FEV1
parameter as primary outcome variable, comparing patients with the 5-5 MIF
MIF Polymorphic Promoter and Cystic Fibrosis
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genotype to the rest of the cohort. The relationship between FEV1 and MIF
genotype was analysed considering both the time to the first acute episode causing
a FEV1 value under 60%, and the ‘‘static’’ FEV1 at last visit (normalised according
to Kulich’s CF-specific reference equations [17]).
Considering the differences in clinical parameters between patients from the
two centres (table 1), the analyses were performed using multivariate techniques.
Cox regression was used to analyse the time to first FEV1 under 60% and patient’s
origin (Verona or Brussels) was included as a covariate together with presence of
MIF 5-5 genotype. Chronic colonization by P. aeruginosa and presence of insulin-
dependent diabetes were not considered because only a minority of patients
displayed these features before first acute episode (28.9% for P.aeruginosa and
5.0% for diabetes). Given the unequal size of 5-5 and X-X groups (patients
number ratio50.09), we used the R package PowerSurvEpi to calculate the power
to detect an effect like the one estimated from our data (Hazard ratio 50.32) with
the number of patients available. The power resulted to be 59%, while the sample
size needed to get 80% power would have been 307 patients. Multiple linear
regression was used to analyse last visit FEV1, including as covariates MIF 5-5
genotype, patients’ origin, chronic colonization by P. aeruginosa and presence of
insulin-dependent diabetes; age was not included because FEV1 values were
already age-normalized according to Kulich. Variance inflation factor was used to
monitor the presence of multicollinearity; its value was below 1.15 for all
covariates.
Power analysis for last visit FEV1 was also used to calculate the power to detect
a medium effect size (0.5, here corresponding to a difference between means of
Table 1. Characteristics of 189 Cystic Fibrosis patients homozygous for the F508del mutation recruited from 2 different European centers.
Brussels Verona p-value
Subjects n 51 138
Female n (%) 22 (%) 78 (%) 0.14
Age, years 21.5¡9.4 24.27¡9.3 0.09
FEV1, Kulich* 67¡24 45¡31 ,0.0001
BMI z-score 20.63¡1.03 20.82¡1.28 0.36
cc by PA n (%) 16 (31.4%) 87 (63.0%) ,0.0002
Diabetes n (%) 11 (21.6%) 40 (29.0%) 0.36
MIF-CATT 5-5 n (%) 4 (7.8%) 12 (8.7%)
MIF-CATT 5-6 n (%) 12 (23.5%) 59 (42.8%)
MIF-CATT 5-7 n (%) 7 (13.7%) 10 (7.2%) 0.11
MIF-CATT 6-6 n (%) 20 (39.2%) 43 (31.2%)
MIF-CATT 6-7 n (%) 8 (15.7%) 12 (8.7%)
MIF-CATT 7-7 n (%) 0 (0%) 2 (1.4%)
Continuous data are presented as mean¡ SD unless otherwise stated; categorical data are presented as counts and proportions. FEV1: forced expiratory
volume in one second; cc by PA: chronic colonization by P. aeruginosa. The most recent FEV1 was used for each patient. MIF-CATT: MIF gene -CATT
repeat genotype at position -794
* CF specific percentile according to Kulich et al, Am J Respir Crit Care Med, 2005.
doi:10.1371/journal.pone.0114274.t001
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15%, which was similar to the estimated difference in our cohort) in an unpaired
t-test with our sample size and considering the unequal size of 5-5 (n516, mean
FEV1550.2, SD531.3) and X-X groups (n5173, mean FEV1564.2, SD525.5).
The power calculated was 48%, while the sample size needed to get 80% power
would have been 382 patients. All analyses were performed using GraphPad Prism
version 5.04 for Windows (GraphPad Software, San Diego California USA, www.
graphpad.com), MedCalc for Windows, version 14.8.1 (MedCalc Software,
Ostend, Belgium) and the R software (R Development Core Team, version 2.9; R
Foundation for Statistical Computing, Vienna, Austria; www.R-project.org).
Power analysis for multiple linear regression was performed with G*Power [19].
Results
Genotyping of the 2794 CATT polymorphic repeats of MIF
promoter (MIF-CATT)
In 189 CF patients, frequencies for 5, 6, 7 and 8 MIF-CATT repeats were 31.7%,
57.4%, 10.9% and 0% respectively. Corresponding values for the 135 healthy
control subjects were similar (28.5%, 60%, 11.1% and 0.4%). In CF patients, MIF-
CATT genotype frequencies were similar among children and adults, excluding a
survival bias for 5-5 subjects.
Clinical status of CF patients and MIF-CATT genotype
Patients were categorized according to the 2794 CATT polymorphic repeats
(MIF-CATT). Anthropometric and clinical data are summarized in Table 1 and
2, and extensively reported in S1 Table.
Given the involvement of MIF in acute inflammation, we focused on FEV1 as
primary outcome variable, comparing patients with the 5-5 MIF-CATT genotype
to the rest of the cohort.
The relationship between FEV1 and MIF genotype was analysed considering
both the time to the first acute episode causing a FEV1 value under 60% and,
secondly, the ‘‘static’’ FEV1 at last visit. Considering the differences in clinical
parameters between patients from the two centres and the possible effect of
diabetes and P. aeruginosa colonization on pulmonary volume, the following
analyses were performed using multivariate techniques.
MIF-CATT 5-5 genotype is associated to a later onset of acute
episodes
Cox regression was used to analyse the time to the first acute episode causing
FEV1 to fall under 60% predicted. MIF-CATT 5-5 genotype and patient’s origin
(Verona or Brussels) were included as independent variables. Chronic coloniza-
tion by P. aeruginosa and presence of insulin-dependent diabetes were not
considered because only a minority of patients displayed these features before first
acute episode (28.9% for P.aeruginosa and 5.0% for diabetes). Both MIF-CATT 5-
MIF Polymorphic Promoter and Cystic Fibrosis
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5 genotype (Hazard Ratio50.327; 95% CI 0.121-0.884) and belonging to the
Brussels cohort (Hazard Ratio50.514; 95% CI 0.310 to 0.849) resulted to be
independent predictors of a later onset of acute episodes (Table 3).
Kaplan-Meier analysis on Fig. 1 shows that age at first acute episode with FEV1
value below 60% predicted was higher in patients with 5–5 genotype compared to
all the other genotypes; median time to event was 29.3 years for 5–5 subjects
compared to 18.2 for the others (Hazard ratio50.35; 95% CI 0.19–0.66; p50.03,
Fig. 1A). Applying per-allele analysis, no relevant differences emerged, consistent
with a recessive effect of 5-CATT allele (Fig. 1B).
MIF-CATT 5-5 genotype shows no association with lower
pulmonary function and P. aeruginosa chronic colonization under
stable conditions
Since recent literature reported that MIF 5-CATT allele also correlates with lower
FEV1 under stable conditions and higher prevalence of P. aeruginosa colonization
[14, 20], we applied multiple linear regression to analyse age-normalized FEV1
[17] under stable conditions, including MIF-CATT 5-5 genotype, patients’ origin,
chronic colonization by P. aeruginosa and presence of insulin-dependent diabetes
as covariates. The only factor not associated with FEV1 resulted to be MIF-CATT
5-5 genotype (table 4). Variance inflation factor was used to monitor the presence
of multicollinearity; its value was below 1.15 for all covariates, indicating no
apparent correlation between MIF-CATT genotype and P. aeruginosa chronic
colonization.
Table 2. Clinical data of 187 Cystic Fibrosis patients homozygous for the F508del mutation according to the genotype for the MIF gene -CATT repeat at
position 2794.
5–5 5–6 5–7 6–6 6–7
n 16 71 17 63 20
Age, years (95%
CI)
18.2 (14.5– 21.9) 23.6 (21.3–25.9) 27.2 (23.1– 31.3) 23.7 (21.2–26.1) 22.3 (18.2–26.5)
BMI z-score (95%
CI)
20.51 (21.10/0.08) 20.84 (21.17/20.52) 21.09 (21.63/20.54) 20.71 (20.97/20.46) 20.62 (21.26/0.01)
FEV1, Kulich*
(95% CI)
64.2 (50.6–77.8) 43.9 (36.6–51.2) 52.4 (37.7–67.08) 53.8 (45.7–61.8) 59.3 (44.8–73.8)
CC by PA – n (%;
95% CI)
5 (31.2%; 13.9–55.8%) 44 (62.0%; 50.3–72.4%) 11 (64.7%; 41.2–82.8%) 33 (52.4%; 40.3–64.2%) 8 (40.0%; 21.8–
61.4%)
Diabetes – n (%;
95% CI)
2 (12.5%; 2.2–37.3%) 22 (31.0%; 21.4–42.5%) 6 (35.3%; 17.2–58.8%) 17 (27.0%; 17.5–39.1) 4 (20.0%; 7.5–
42.2%)
Data are presented as mean and 95% Confidence Interval (95% CI). FEV1: forced expiratory volume in one second; BMI: body mass index; cc by PA:
chronic colonization by P. aeruginosa.
* CF specific percentile according to Kulich et al, Am J Respir Crit Care Med, 2005.
doi:10.1371/journal.pone.0114274.t002
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Discussion
In this study, 8% of 189 CF patients homozygous for the F508del CFTR mutation
carried the 5-5 allele combination for a functional CATT repeat polymorphism in
the MIF gene promoter (MIF-CATT), which is expected to be associated with
decreased pro-inflammatory activity. Patients carrying this genotype showed a
later onset of acute episodes; the rate of lung function decline, as assessed by age at
the first FEV1 value below 60% predicted, was lower in this group (table 3). By
contrast, no apparent link was found with FEV1 and chronic P. aeruginosa
colonization under stable conditions at multivariate regression analysis (table 4).
Overall, our data support the role of MIF as a modifier gene of lung disease in CF
only to a very limited extent, in contrast to what suggested by Plant et al. [14] and
Adamali et al. [20], though the results of both studies differ from ours in several
aspects. These authors identified MIF-CATT genotype in 167 adult white CF
patients from a single centre, 11% of whom were pancreatic sufficient. Only a
fraction of patients (57%) were homozygous for the F508del mutation while 35%
were heterozygous for this mutation and the remaining 8% were heterozygous for
other CFTR mutations. Patients carrying at least one copy of the 5-repeat MIF-
CATT allele were found to have a decreased incidence of P. aeruginosa
colonization (defined as the presence of bacteria in the sputum) and a significant
reduction in the risk of pancreatic insufficiency.
The results of Plant et al. were partly reproduced (only for FEV and FVC) by
Adamali et al. in a recent publication of the same research team [20], with a
cohort of 143 patients selected from the same referral centre on the basis of a CF
diagnosis and not of a F508del genotype. This work presents the same
heterogeneous genetic background as in Plant et al., and the same differences
compared to our data. Moreover, an unspecified fraction of the patients from this
latter study were also enrolled in the former. Interestingly, the ex-vivo part of the
work by Adamali et al. showing differences of MIF levels in plasma and peripheral
blood monocytes from CF patients, relies only on individuals with 5-5 and 6-6
MIF genotypes. In these experiments, the 5-5 MIF genotype is confirmed to be the
genotype with lowest expression of the protein.
Table 3. Cox regression analysis for age at first acute episode with FEV1 ,60% of predicted value on 185 Cystic Fibrosis patients homozygous for the
F508del mutation.
Variable Value Hazard Ratio 95% CI p-value
MIF-CATT genotype X-X 1 - -
5–5 0.325 0.120–0.878 0.027
Centre of origin Verona 1 - -
Brussels 0.510 0.309–0.843 0.0090
Number of patients with acute episode 5119
Number of censored patients566
Overall significance p-value 50.0010
MIF-CATT genotype: MIF gene -CATT repeat genotype at position 2794
95% CI 595% Confidence Interval
doi:10.1371/journal.pone.0114274.t003
MIF Polymorphic Promoter and Cystic Fibrosis
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MIF-CATT genotype distribution in patients and controls were comparable in
both studies (S2 Table). However, we found that clinical benefit was restricted to
later onset of acute episodes in patients homozygous for the 5-repeats MIF-CATT
allele.
Aside from these discrepancies, our results are in keeping with the observation
by Baugh et al. [13] that in the context of another inflammatory disease
(rheumatoid arthritis), only homozygosity for the 5-repeats MIF-CATT allele was
protective against the development of severe disease.
Research into CF modifier genes has often yielded conflicting results and
numerous challenges have been identified [21]; methodological issues are also
Fig. 1. Lung function decline in 185 Cystic Fibrosis patients grouped according to MIF -794 CATT
genotypes. Kaplan-Meier plots relative to age at first acute episode with FEV1 ,60% of predicted value. (A)
Comparison between patients with MIF 5-5 (homozygous 5-CATT repeats) vs. not 5-5 genotype; (B)
comparison between patients with at least one 5-CATTallele vs. the others. Ticks indicate censored subjects
follow-up times. ‘‘Number at risk’’ at the bottom indicates the number of patients without acute episodes at a
given time interval and whose follow- up extends at least that far into the curve.
doi:10.1371/journal.pone.0114274.g001
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likely to be involved. When compared to the earlier study, several strengths of the
present work can be stressed. The study population is homogenous at the CF
locus, since we focused on a single CFTR genotype. The centres involved have
been routinely using reliable CF-specific electronic databases for a substantial
period of time. Additional efforts were made to normalize data, using CF-specific
FEV1 predicted values and multivariate analysis to accout for centre-dependent
variations. Z-score for BMI is now considered a more appropriate index
expression of nutrition than percentage of ideal body weight [22] and chronic
colonization by P. aeruginosa is clinically more relevant than airway colonization
(simply referring to its presence). A large GWAS study on CF patients failed to test
MIF as a modifier gene due to the lack of probes for this gene in the used DNA
arrays; indeed the whole MIF gene is not covered by the Illumina 610-Quad
platform used for genotyping. As for possible SNPs in linkage disequilibrium with
MIF-CATT, the study used three different cohorts of patients for a total of 3467
CF patients; a sample size that, as the authors themselves stated, is several-fold
smaller than the standard for GWAS studies. This implies that only strongest
associations might emerge from the study. Due to the small number of MIF 5-
CATT subjects and to the fact that, at least from our data, a moderate effect is
suggested only in recessive homozygotes, such an effect would have probably been
difficult to detect in any case [23]. Altogether the two previously available studies
involved an undefined number of CF patients between 167 and 356. This might
still be insufficient [24], given the wide range of FEV1 values and the low
prevalence of the homozygous 5-CATT MIF promoter allele, so further work is
encouraged. Besides clinical data, biologic plausibility of a candidate modifier
gene is essential and the case of MIF gene is a good example. Indeed, it is a key
pro-inflammatory mediator that is implicated in the pathogenesis of inflamma-
tory diseases such as asthma, rheumatoid arthritis and acute respiratory distress. It
has also been shown to sustain toll-like receptor 4 expression in murine
macrophages [25]. Alveolar macrophages are believed to play an important role in
regulating the local inflammatory and immune responses in the CF lung [26229].
In addition, both macrophages [30] and their circulating precursors, monocytes
Table 4. Multiple regression analysis of FEV1 (Kulich)* data on 189 Cystic Fibrosis patients homozygous for the F508del mutation.
Variable Coefficient SE r-partial P
Constant 60.96 - - -
MIF-CATT genotype 55-5 7.06 7.09 0.073 0.320
Centre of origin 5 Brussels 15.15 4.58 0.24 0.001
CC by PA 216.79 4.16 20.29 0.0001
Diabetes 219.04 4.46 20.30 ,0.0001
Overall R250.274; multiple correlation coefficient 50.524
Overall significance p-value,0.0001;
FEV1: forced expiratory volume in one second; cc by PA: chronic colonization by P. aeruginosa. MIF-CATT genotype: MIF gene -CATT repeat genotype at
position -794
*CF specific percentile according to Kulich et al, Am J Respir Crit Care Med, 2005.
doi:10.1371/journal.pone.0114274.t004
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[31], have been shown to express functional CFTR, with alveolar macrophages
from CFTR -/- mice exhibiting defective killing of internalized bacteria [30]. In
Cystic Fibrosis, a vicious circle of inflammation and infection leads to destruction
of obstructed airways, and it is notable that, up to now, only 4 medications - all
with direct or indirect anti-inflammatory properties - are known to slow FEV1
rate of decline in this disease: high-dose ibuprofen [32], inhaled corticosteroids
[20, 33, 34], macrolides [35] and DNase [36]. Conceivably, identification of
modifier genes of lung disease in CF should help to provide novel therapeutic
targets. In this perspective, neutralizing MIF activity by using antibodies or gene
knockout, protected mice against severe sepsis by E. coli [11] and Pseudomonas
and also enhanced P. aeruginosa airway clearance [10]. Furthermore, several
powerful tautomerase inhibitors, highly selective for human MIF, have recently
been identified and Adamali et al. showed promising ex-vivo results regarding
their use to tame MIF-sustained immune reaction in CF patients [20, 37, 38]. In
conclusion, we have provided additional independent data supporting the role of
MIF as a modifier gene of lung disease in CF; the beneficial effect, however, was
limited to the homozygous genotype displaying the lowest transcriptional activity.
Since the protective MIF genotype is rare, most CF patients could benefit from a
targeted approach aimed at reducing the powerful inflammatory response
associated with high expression of this gene.
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